Zidovudine has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Zidovudine studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
WE066, EPI40007 IV The Antiretroviral Pregnancy Registry (APR, Registry)
WE490 IV Lactic acid levels in children prenatally and perinatally treated with antiretrovirals to prevent HIV transmission.
COD20002 II A Phase II, Open-Label, Multicenter, Randomized, Parallel Group, 14 Day Pilot Study of Monotherapy with Zidovudine 600mg Once Daily Compared to Zidovudine 300mg Twice Daily in HIV-Infected, Antiretroviral-Naïve Subjects.
COD10001 I A pilot open-labeled, randomized, parallel cohort, pharmacokinetic and pharmacodynamic, multicenter trial of zidovudine (RETROVIR) 600 mg once daily compared to zidovudine 300 mg BID monotherapy for 14 days in HIV infected, therapy naïve patients.
P53-19 (27,433 -19) I Retrovir® Capsules in the Treatment of HIV-Infected Patients in Renal Failure